Q1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?
a. Advanced oesophageal cancer
b. Myelofibrosis
Q2. Please provide the total number of patients treated in the last 6 months for:
a. Myelofibrosis
b. Myelofibrosis – patients over the age 65
c. Oesophageal cancer (any type)
d. Oesophageal adenocarcinoma
e. Oesophageal squamous cell carcinoma
f. Unresectable Oesophageal squamous cell carcinoma
Q3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with?
a. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
b. Any other systemic anti-cancer therapy
c. Palliative care only
Q4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with?
a. Ruxolitinib
b. Hydroxyurea
c. Watch and wait approach
Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Myelofibrosis and Oesophageal cancer. 050121